{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:15:47Z","timestamp":1791404147622,"version":"4.3.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Capital Construction Funds within the provincial budget in 2020","award":["2020C038-1"],"award-info":[{"award-number":["2020C038-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40259-022-00563-5","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T10:17:12Z","timestamp":1669198632000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct04371185","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Min","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"5","key":"563_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00006416-200409000-00006","volume":"23","author":"A Tam","year":"2004","unstructured":"Tam A, Geier KA. Psoriatic arthritis. Orthop Nurs. 2004;23(5):311\u20134.","journal-title":"Orthop Nurs"},{"issue":"3","key":"563_CR2","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314\u201321.","journal-title":"J Autoimmun"},{"issue":"5","key":"563_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1684\/ejd.2012.1802","volume":"22","author":"X Ding","year":"2012","unstructured":"Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663\u20137.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"563_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaad.2004.07.045","volume":"52","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"563_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1684\/ejd.2011.1559","volume":"22","author":"Y Wu","year":"2012","unstructured":"Wu Y, Chen J, Li YH, Ma GZ, Chen JZ, Gao XH, et al. Treatment of psoriasis with interleukin-12\/23 monoclonal antibody: a systematic review. Eur J Dermatol. 2012;22(1):72\u201382.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"563_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4081\/reumatismo.2020.1266","volume":"72","author":"FM Perrotta","year":"2020","unstructured":"Perrotta FM, Delle Sedie A, Scriffignano S, Volpe P, Cordisco E, Milano N, et al. Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12\/23 and IL-17 inhibitors: a multicenter prospective study. Reumatismo. 2020;72(1):52\u20139.","journal-title":"Reumatismo"},{"issue":"6","key":"563_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535\u201345.","journal-title":"MAbs"},{"issue":"12","key":"563_CR8","doi-asserted-by":"publisher","first-page":"675358","DOI":"10.3389\/fphar.2021.675358","volume":"18","author":"L Gao","year":"2021","unstructured":"Gao L, Li Q, Zhang H, Wu M, Fang M, Yang L, et al. Biosimilarity study between QX001S and ustekinumab in healthy Chinese male subjects. Front Pharmacol. 2021;18(12):675358. https:\/\/doi.org\/10.3389\/fphar.2021.675358 (eCollection 2021).","journal-title":"Front Pharmacol"},{"key":"563_CR9","unstructured":"Centocor Ortho Biotech Inc. Stelara\u2122 (ustekinumab): prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125261s154,761044s006lbl.pdf. Accessed Dec 2020."},{"issue":"3","key":"563_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/CVI.00415-08","volume":"16","author":"RD Marchese","year":"2009","unstructured":"Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, et al. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol. 2009;16(3):387\u201396.","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"563_CR11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/clinchem\/37.9.1534","volume":"37","author":"GF Blackburn","year":"1991","unstructured":"Blackburn GF, Shah HP, Kenten JH, Leland J, Kamin RA, Link J, et al. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clin Chem. 1991;37(9):1534\u20139.","journal-title":"Clin Chem"},{"key":"563_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Guidelines for bioequivalence studies of generic products. 2015. http:\/\/www.pmda.go.jp\/files\/000157415.pdf. Accessed 12 Jun 2015."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00563-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00563-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00563-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:16:48Z","timestamp":1744715808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00563-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00563-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"19 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was financially supported by the Capital Construction Funds within the provincial budget in 2020 (innovation capacity construction, Project No. 2020C038-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YQ, JY, XY, ZW, and CG are employees of Bio-Thera Solutions, Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The Ethics Committee of Jilin University First Hospital Clinical Research Institute in Changchun City (Jilin Province, China) approved the protocols of our study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data and material are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MW and YD performed a review of the topic, and wrote and revised the manuscript. HZ and DY took part in analyzing the pharmacokinetic data. YQ, JY, and XL drafted part of the manuscript. YQ, JY, XY, ZW, and CG helped with the analysis and interpretation of the data, and prepared all the figures and tables. YD contributed to the writing of the manuscript and provided critical revisions. All authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}